alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 71.30 Payment for care and treatment. ( a ) The Director may authorize payment for the care and treatment of individuals subject to medical examination, quarantine, isolation, and conditional release, subject to paragraphs (b) through (h) of this section.
( b ) Payment for care and treatment shall be in the Director's sole discretion and subject to the availability of appropriations.
( c ) Payment shall be secondary to the obligation of the United States or any third-party (including any State or local governmental entity, private insurance carrier, or employer), under any other law or contractual agreement, to pay for such care and treatment, and shall be paid by the Director only after all third-party payers have made payment in satisfaction of their obligations.
( d ) Payment may include costs for providing ambulance or other medical transportation when such services are deemed necessary by the Director for the individual's care and treatment.
( e ) Payment shall be limited to those amounts the hospital, medical facility, or medical transportation service would customarily bill the Medicare system using the International Classification of Diseases, Clinical Modification (ICD-CM), and relevant regulations promulgated by the Centers for Medicare and Medicaid Services in existence at the time of billing.
( f ) For quarantinable communicable diseases, payment shall be limited to costs for services and items reasonable and necessary for the care and treatment of the individual for the time period beginning when the Director refers the individual to the hospital or medical facility and ends when, as determined by the Director, the period of apprehension, quarantine, isolation, or conditional release expires.
( g ) For diseases other than those described in paragraph (f) of this section, such payment shall be limited to costs for services and items reasonable and necessary for care and treatment of the individual for the time period that begins when the Director refers the individual to the hospital or medical facility and ends when the individual's condition is diagnosed, as determined by the Director, as an illness other than a quarantinable communicable disease.
( h ) For ambulance or other medical transportation, payment shall be limited to the costs for such services and other items reasonable and necessary for the safe medical transport of the individual.
[82 FR 6975, Jan. 19, 2017]
§ 493.1242 Standard: Specimen submission, handling, and referral. ( a ) The laboratory must establish and follow written policies and procedures for each of the following, if applicable: ( 1 ) Patient preparation.
( 2 ) Specimen collection.
( 3 ) Specimen labeling, including patient name or unique patient identifier and, when appropriate, specimen source.
( 4 ) Specimen storage and preservation.
( 5 ) Conditions for specimen transportation.
( 6 ) Specimen processing.
( 7 ) Specimen acceptability and rejection.
( 8 ) Specimen referral.
( b ) The laboratory must document the date and time it receives a specimen.
( c ) The laboratory must refer a specimen for testing only to a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by CMS.
( d ) If the laboratory accepts a referral specimen, written instructions must be available to the laboratory's clients and must include, as appropriate, the information specified in paragraphs (a)(1) through (a)(7) of this section.
HomeTreaties and International Agreements

# Treaties and International Agreements

129 items

        -    Remarks  		Secretary Antony J. Blinken at a Press Availability	  Antony J. BlinkenAugust 1, 2022United Nations HeadquartersNew York, New York 
        -    Special Briefing via Telephone  		Telephonic Press Briefing with Juan Gonzalez, National Security Council Senior Director for the Western Hemisphere and Brian A. Nichols, Assistant Secretary of State for Western Hemisphere Affairs, Bureau of Western Hemisphere Affairs	  Brian A. NicholsJune 1, 2022 
        -    		U.S.-ASEAN Summit	  May 9, 2022 
        -    Special Briefing via Telephone  		Special Briefing via Telephone with Jennifer Gavito, Deputy Assistant Secretary for Iraq and Iran	  Jennifer GavitoApril 22, 2022 
        -    DipNote  		Peaceful Uses of Nuclear Science and Technology in Food and Agriculture	  November 24, 2021 
        -    DipNote  		Using Nuclear Science and Technology to Save Lives	  November 22, 2021 
        -    Remarks to the Press  		Secretary Antony J. Blinken and Iceland Foreign Minister Gudlaugur Thor Thordarson Before Their Meeting	  Antony J. BlinkenMay 18, 2021Harpa Concert Hall and Conference CenterReykjavik, Iceland 
        -    Remarks  		Secretary Antony J. Blinken and Danish Foreign Minister Jeppe Kofod at a Joint Press Availability	  Antony J. BlinkenMay 17, 2021Eigtveds PakhusCopenhagen, Denmark 
        -    Remarks  		Secretary Antony J. Blinken Virtual Remarks at the UN Security Council Open Debate on Multilateralism	  Antony J. BlinkenMay 7, 2021Washington, DC 
        -    Readout  		Secretary Blinken’s Meeting with UK Prime Minister Johnson	  May 4, 2021 

previous page1…34567…13next page

Back to Top
#### § 10.25 Payment of death claim on adjusted service certificate without bond.

If the veteran named in the adjusted service certificate, issued pursuant to the provisions of section 501 of the World War Adjusted Compensation Act, is deceased, and if the certificate was lost or destroyed wholly or in part or was so defaced as to impair its value prior to receipt by the veteran, or was partially destroyed or defaced after receipt by the veteran, but can be identified to the satisfaction of the Secretary of Veterans Affairs, payment will be made of the proceeds of the certificate, a bond of indemnity will not be required, and a duplicate adjusted service certificate will not be issued: *Provided,* The person entitled to payment thereon surrenders the defaced or mutilated certificate or so much thereof as may remain.
# Fourth Court of Appeals

San Antonio, Texas

July 31, 2017

No. 04

- 17

- 00285

- CV

MEDICAL IMAGING SOLUTIONS GROUP, INC. OF TEXAS

, Appellant

v.

WESTLAKE MEDICAL OF AUSTIN, LTD . d/b/a The Hospital at Westlake Medical Center, WLMA, LC, Westlake Surgical, LP d/b/a/ The Hospital at Westlake and WS GP, LLC, Appellees

From the 224th Judicial District Court, Bexar County, Texas

Trial Court No. 2014CI06112

Honorable Ca thleen M. Stryker, Judge Presiding



### O R D E R

On June 26, 2017, Appellant Medical Imaging Solutions Group Inc. of Texas filed a petition to review and access sealed records, specifically the clerk ’s record, volume 3. On July 24, 2017, Appellant filed a certificate of conference indicated that he conferred with counsel for Appellee s Westlake Surgical LP d/b/a The Hospital at Westlake and WS GP, LLC

, and that counsel for both parties agree the parties “should and ne ed access to the sealed records that are part of the Clerk’s Record filed in this matter.” Accordingly, Appellant’s motion is GRANTED, and the attorneys are directed to contact the Clerk of this court to make arrangements to review

the sealed record. All parties and their attorneys are ORDERED: (1) to fully comply with the instructions provided by the Clerk of this court regarding their access to the sealed record; and (2) not to share the contents of the sealed record with any person except to the extent necessary to prepare their respective briefs.

In the event Appellant or Appellees reference the sealed record in their respective briefs, they are ORDERED to (1) file their respective briefs in paper form only, (2) with a cover letter informing the Cler k of this court that the brief references the sealed record. See T EX

. R. A PP

. P. 9.2(c)(3) (exception to electronic filing for documents under seal).

_________________________________ Patricia O. Alvarez, JusticeIN WITNESS WHEREOF, I have hereunto s et my hand and affixed the seal of the said

court on this 31st day of July, 2017

.

___________________________________ Luz Estrada Chief Deputy Clerk
Opinion filed August 4, 2022

 

In The

Eleventh Court of Appeals __________

No. 11-21-00166-CR

__________

JOSE ANGEL SILVA, Appellant

V.

THE STATE OF TEXAS, Appellee

On Appeal from the 70th District Court

Ector County, Texas

Trial Court Cause No. A-20-1131-CR

M E M O R A N D U M O P I N I O N

The jury convicted Appellant, Jose Angel Silva, of the offense of continuous 

sexual abuse of a young child. See TEX. PENAL CODE ANN. § 21.02 (West Supp. 

2021). The jury assessed Appellant’s punishment at imprisonment for life, and the 

trial court sentenced him accordingly. We affirm.

Appellant’s court-appointed counsel has filed in this court a motion to 

withdraw. The motion is supported by a brief in which counsel professionally and 

conscientiously examines the record and applicable law and concludes that the 
2

appeal is frivolous and without merit. Counsel provided Appellant with a copy of 

the brief, a copy of the motion to withdraw, and a copy of both the clerk’s record 

and the reporter’srecord. Counsel advised Appellant of hisright to review the record 

and file a response to counsel’s brief. Counsel also advised Appellant of his right to

file a petition for discretionary review with the clerk of the Texas Court of Criminal 

Appeals seeking review by that court. See TEX. R. APP. P. 68. Court-appointed 

counsel has complied with the requirements of Anders v. California, 386 U.S. 738 

(1967); Kelly v. State, 436 S.W.3d 313 (Tex. Crim. App. 2014); In re Schulman, 252 

S.W.3d 403 (Tex. Crim. App. 2008); and Stafford v. State, 813 S.W.2d 503 (Tex. 

Crim. App. 1991). 

Appellant has not filed a response to counsel’s Anders brief. Following the 

procedures outlined in Anders and Schulman, we have independently reviewed the 

record, and we agree that the appeal is frivolous and without merit.1

 

We grant counsel’s motion to withdraw, and we affirm the judgment of the 

trial court. 

PER CURIAM

August 4, 2022

Do not publish. See TEX. R. APP. P. 47.2(b).

Panel consists of: Bailey, C.J.,

Trotter, J., and Williams, J.

1

We note that Appellant has a right to file a petition for discretionary review pursuant to Rule 68 

of the Texas Rules of Appellate Procedure.
§ 382.21 Royalty fees for the public performance of sound recordings and the making of ephemeral recordings by SDARS. ( a ) *Royalty fees.* Commencing January 1, 2018, and continuing through December 31, 2027, Licensees must pay royalty fees for all Eligible Transmissions of sound recordings at the rate of 15.5% of Gross Revenues.
( b ) *Ephemeral recordings royalty fees.* ( 1 ) The fee for all Ephemeral Recordings is part of the total fee payable under this section and constitutes 5% of it. All Ephemeral Recordings that a Licensee makes that are necessary and commercially reasonable for making noninteractive Digital Audio Transmissions as an SDARS are included in the 5%.
( 2 ) The minimum fee is $5,000 per year.
**Exhibit 31(a)****CERTIFICATION PURSUANT TO RULE 13a-14(a) and 15d-14(a)**I, Gregory B. Kalush, certify that: 1. I have reviewed this report on Form 10-Q of Interphase Corporation (the “Company”);  2. Based on my knowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report;  3. Based on my knowledge, the financial statements, and other financial information included inthis report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the Company as of, and for, the periods presented in this report;  4. The Company’s other certifying officer and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and15d-15(f)) for the Company and have:(a) Designed such disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that material information relating tothe Company, including its consolidated subsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report is being prepared;(b) Designed such internal control over financial reporting, or caused such an internal controlover financial reporting to be designed under our supervision, to provide reasonable assuranceregarding the reliability of financial reporting and the preparation of financial statements forexternal purposes in accordance with generally accepted accounting principles;(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on such evaluation; and(d) Disclosed in this report any change in the Company’s internal control over financialreporting that occurred during the Company’s most recent fiscal quarter that has materiallyaffected, or is reasonably likely to materially affect, the Company’s internal control overfinancial reporting; and 5. The Company’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the Company’s auditors and theaudit committee of the Company’s board of directors:(a) All significant deficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adversely affect the Company’sability to record, process, summarize and report financial information; and(b) Any fraud, whether or not material, that involves management or other employees who have asignificant role in the Company’s internal control over financial reporting.         Date: November 9, 2007   Signature: /s/ Gregory B. Kalush                      Chief Executive Officer
[Federal Register Volume 74, Number 185 (Friday, September 25, 2009)]
[Notices]
[Page 48984]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-23068]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the Medical 
Imaging Study Section, October 5, 2009, 8 a.m. to October 5, 2009, 4 
p.m., Four Points by Sheraton Washington DC Downtown, 1201 K Street, 
NW., Washington, DC, 20005 which was published in the Federal Register 
on September 16, 2009, 74 FR 47589-47592.
    The meeting will be held October 4, 2009, 7 p.m. to October 5, 
2009, 5 p.m. The meeting location remains the same. The meeting is 
closed to the public.

    Dated: September 18, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-23068 Filed 9-24-09; 8:45 am]
BILLING CODE 4140-01-M
###### Editorial Note on Part 84

#### Editorial Note:

Nomenclature changes to part 84 appear at 69 FR 18803, Apr. 9, 2004.

#### § 84.197 Respirator containers; minimum requirements.

Respirators shall be equipped with a substantial, durable container bearing markings which show the applicant's name, the type and commercial designation of the respirator it contains and all appropriate approval labels.
§ 81.11 Use of uncertainty analysis in NIOSH-IREP. ( a ) EEOICPA requires use of the uncertainty associated with the probability of causation calculation, specifically requiring the use of the upper 99% confidence interval (credibility limit) estimate of the probability of causation estimate. As described in the NCI document,[2] uncertainty from several sources is incorporated into the probability of causation calculation performed by NIOSH-IREP. These sources include uncertainties in estimating: radiation dose incurred by the covered employee; the radiation dose-cancer relationship (statistical uncertainty in the specific cancer risk model); the extrapolation of risk (risk transfer) from the Japanese to the U.S. population; differences in the amount of cancer effect caused by different radiation types (relative biological effectiveness or RBE); the relationship between the rate at which a radiation dose is incurred and the level of cancer risk produced (dose and dose rate effectiveness factor or DDREF); and, the role of non-radiation risk factors (such as smoking history).
( b ) NIOSH-IREP will operate according to the same general protocol as IREP for the analysis of uncertainty. It will address the same possible sources of uncertainty affecting probability of causation estimates, and in most cases will apply the same assumptions incorporated in IREP risk models. Different procedures and assumptions will be incorporated into NIOSH-IREP as needed, according to the criteria outlined under § 81.10.
Footnotes -
81.11
[2] Draft Report of the NCI-CDC Working Group to Revise the 1985 NIH Radioepidemiological Tables, May 31, 2000, p. 17-18, p. 22-23.
Exhibit 32.2

                      AXA EQUITABLE LIFE INSURANCE COMPANY

    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarter ended March
31, 2005 of AXA Equitable Life Insurance Company (the "Company") as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
Stanley B. Tulin, Vice Chairman of the Board and Chief Financial Officer of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:


        (1) the Report fully complies with the  requirements of Section 13(a) or
            15(d) of the Securities Exchange Act of 1934, as amended; and

        (2) the  information contained in the Report fairly  presents, in all
            material respects, the financial condition and results of operations
            of the Company.


                                        /s/ Stanley B. Tulin
                                        --------------------
                                        Stanley B. Tulin
                                        Vice Chairman of the Board and
                                        Chief Financial Officer
         Date: May 13, 2005
### RE: A couple of additional points related to past reliance on SO 2 modeling Lydia Wegman to: Laity, James A. 06/01/2010 08:11 PM Cc: "Mancini, Dominic J.", Tricia Crabtree

Thanks Jim. -----"Laity, James A." <James

_ A.

_ Laity@omb.eop.gov> wrote: -----

To: Lydia Wegman/RTP/USEPA/US@EPA From: "Laity, James A." <James

_ A.

_ Laity@omb.eop.gov> Date: 06/01/2010 07:47PM cc: "Mancini, Dominic J." <Dominic

_ J.

_ Mancini@omb.eop.gov> Subject: RE: A couple of additional points related to past reliance on SO2 modeling



### Thanks, I have reviewed the 2002 FR notice on the Billings/Laurel SIP. The modeling v. monitoring discussion is very informative. ‐‐ j im

From: Wegman.Lydia@epamail.epa.gov [ mailto:Wegman.Lydia@epamail.epa.gov] Sent: Tuesday, June 01, 2010 6:39 PM To: Laity, James A. Cc: Mancini, Dominic J.; thrift.mike@epamail.epa .gov; Mclean.Kevin@epamail.epa.gov; schneeberg.sara@epamail.epa.gov; Wallace.Larry@epamail .epa.gov; Crabtree.Tricia@epamail.epa.gov Subject: A couple of additional points related to past reliance on SO2 modeling

Please see Mike Thrift''s note below.

From: Mike Thrift/DC/USEPA/US

To: Lydia Wegman/RTP/USEPA/US@EPA

Cc: Sara Schneeberg/DC/USEPA/US@EPA, Kevin McLean/DC/USEPA/US@EPA

Date: 06/01/2010 06:36 PM
Subject: Re: Language related to past reliance on SO2 modeling

Lydia-- The typos in that quote are my fault. It should be "occurring," and the first page cite should be "40412." Also, for a much longer discussion on the "Effect of 'Contradictory' Monitoring Data" as that subject was addressed in a more modern action, see the Final Rule for the Billings/Laurel SO2 SIP, 67 FR 22167, 22185-87 (May 2, 2002).
EXHIBIT 32
                                                                      ----------

          CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
            PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned have executed this certification in connection with the filing
with the Securities and Exchange Commission of the Company's Quarterly Report on
Form 10-Q for the period ending June 30, 2008. The undersigned hereby certify
that to our knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.


Dated: August 14, 2008                /s/ Raul S. McQuivey
                                      --------------------------------
                                      Raul S. McQuivey
                                      President and Chief Executive Officer
                                      (Principal Executive Officer)


Dated: August 14, 2008                /s/ Sidney C. Hooper
                                      --------------------------------
                                      Sidney C. Hooper
                                      Chief Financial Officer
                                      (Principal Accounting Officer)
- Office of the Spokesperson
- Briefing Schedule
- Press Briefings
- Press Releases
- Public Schedule
- 2017-2021 Archive

HomeOffice of the Spokesperson...Public Schedule

# 						Public Schedule					

							Collection of U.S. Department of State Public Schedules. 						

		Subscribe		

944 items
Clear All Filters

## View collection by:

Select a Year2024202320222021

Select a MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember

Select a Release TypePublic Schedule

Select a Bureau/OfficeDeputy Secretary of StateOffice of the SpokespersonThe Secretary of State

          -    Public Schedule  		Public Schedule – April 1, 2024	  April 1, 2024 
          -    Public Schedule  		Public Schedule – March 29, 2024	  March 28, 2024 
          -    Public Schedule  		Public Schedule – March 28, 2024	   
          -    Public Schedule  		Public Schedule – March 27, 2024	  March 26, 2024 
          -    Public Schedule  		Public Schedule – March 26, 2024	  March 25, 2024 
          -    Public Schedule  		Public Schedule – March 25, 2024 (Updated)	  March 25, 2024 
          -    Public Schedule  		Public Schedule – March 22, 2024	  March 21, 2024 
          -    Public Schedule  		Public Schedule – March 21, 2024	  March 20, 2024 
          -    Public Schedule  		Public Schedule – March 20, 2024	  March 20, 2024 
          -    Public Schedule  		Public Schedule – March 19, 2024	  March 18, 2024 

previous page1…45678…95next page

Back to Top